183 related articles for article (PubMed ID: 26894970)
1. Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.
Yu Z; Li T; Wang C; Deng S; Zhang B; Huo X; Zhang B; Wang X; Zhong Y; Ma X
Oncotarget; 2016 Mar; 7(13):15725-37. PubMed ID: 26894970
[TBL] [Abstract][Full Text] [Related]
2. Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.
Fu R; Chen Y; Wang XP; An T; Tao L; Zhou YX; Huang YJ; Chen BA; Li ZY; You QD; Guo QL; Wu ZQ
Oncotarget; 2016 Feb; 7(5):5715-27. PubMed ID: 26735336
[TBL] [Abstract][Full Text] [Related]
3. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells.
Yao R; Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Gao J; Xu K
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30068698
[TBL] [Abstract][Full Text] [Related]
5. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
Crawford LJ; Campbell DC; Morgan JJ; Lawson MA; Down JM; Chauhan D; McAvera RM; Morris TC; Hamilton C; Krishnan A; Rajalingam K; Chantry AD; Irvine AE
Oncogene; 2020 Jul; 39(27):5001-5014. PubMed ID: 32523091
[TBL] [Abstract][Full Text] [Related]
6. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
7. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
8. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
9. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
[TBL] [Abstract][Full Text] [Related]
10. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
[TBL] [Abstract][Full Text] [Related]
11. Addiction to c-MYC in multiple myeloma.
Holien T; Våtsveen TK; Hella H; Waage A; Sundan A
Blood; 2012 Sep; 120(12):2450-3. PubMed ID: 22806891
[TBL] [Abstract][Full Text] [Related]
12. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha MN; Abdi J; Yang Y; Chang H
Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
[TBL] [Abstract][Full Text] [Related]
13. The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.
Zeng Y; Zhang Y; Cui Z; Mao J; Xu J; Yao R
Chem Res Toxicol; 2024 Jun; 37(6):1062-1069. PubMed ID: 38815162
[TBL] [Abstract][Full Text] [Related]
14. DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.
Zhang Q; Gong W; Wu H; Wang J; Jin Q; Lin C; Xu S; Bao W; Wang Y; Wu J; Feng S; Zhao C; Chen B; Liu Z
Carcinogenesis; 2021 Oct; 42(10):1223-1231. PubMed ID: 34546340
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Li H; Fang Y; Niu C; Cao H; Mi T; Zhu H; Yuan J; Zhu J
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9317-E9324. PubMed ID: 30181285
[TBL] [Abstract][Full Text] [Related]
16. E3 ubiquitin ligase FBW7α inhibits cholangiocarcinoma cell proliferation by downregulating c-Myc and cyclin E.
Li M; Ouyang L; Zheng Z; Xiang D; Ti A; Li L; Dan Y; Yu C; Li W
Oncol Rep; 2017 Mar; 37(3):1627-1636. PubMed ID: 28184929
[TBL] [Abstract][Full Text] [Related]
17. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
18. Fucoidan inhibits angiogenesis induced by multiple myeloma cells.
Liu F; Luo G; Xiao Q; Chen L; Luo X; Lv J; Chen L
Oncol Rep; 2016 Oct; 36(4):1963-72. PubMed ID: 27498597
[TBL] [Abstract][Full Text] [Related]
19. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
20. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.
Li K; Wang F; Yang ZN; Zhang TT; Yuan YF; Zhao CX; Yeerjiang Z; Cui B; Hua F; Lv XX; Zhang XW; Yu JJ; Liu SS; Yu JM; Shang S; Xiao Y; Hu ZW
Nat Commun; 2020 Dec; 11(1):6316. PubMed ID: 33298911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]